M. Nijenhuis

发表

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

H. Guchelaar, J. Swen, J. Swen, 2011, Clinical pharmacology and therapeutics.

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs

R. V. van Schaik, J. Swen, M. Nijenhuis, 2021, European Journal of Human Genetics.

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines

H. Guchelaar, R. V. van Schaik, J. Swen, 2019, European Journal of Human Genetics.

Familial neurohypophysial diabetes insipidus in a large Dutch kindred: effect of the onset of diabetes on growth in children and cell biological defects of the mutant vasopressin prohormone.

J. Burbach, M. Nijenhuis, E. L. van den Akker, 2001, The Journal of clinical endocrinology and metabolism.

Mutations in the Vasopressin Prohormone Involved in Diabetes Insipidus Impair Endoplasmic Reticulum Export but Not Sorting*

J. Burbach, M. Nijenhuis, R. Zalm, 1999, The Journal of Biological Chemistry.

The endoplasmic reticulum‐resident stress protein gp96 binds peptides translocated by TAP

H. Rammensee, S. Stevanović, M. Nijenhuis, 1997, European journal of immunology.

EFFECT OF A HOLISTIC MEAL AND AMBIANCE CONCEPT ON MAIN MEAL ENJOYMENT AND FOOD INTAKE OF DUTCH NURSING HOME RESIDENTS: A PILOT STUDY

S. Kremer, M. Nijenhuis, M. Gorselink, 2012 .

Major histocompatibility complex class II molecules induce the formation of endocytic MIIC-like structures

J. Neefjes, J. Calafat, M. Nijenhuis, 1994, The Journal of cell biology.

A diabetes insipidus vasopressin prohormone altered outside the central core of neurophysin accumulates in the endoplasmic reticulum

J. Burbach, M. Nijenhuis, R. Zalm, 2000, Molecular and Cellular Endocrinology.

Targeting major histocompatibility complex class II molecules to the cell surface by invariant chain allows antigen presentation upon recycling

J. Neefjes, J. Calafat, M. de Haas, 1994, European journal of immunology.

The Hormone Domain of the Vasopressin Prohormone is Required for the Correct Prohormone Trafficking Through the Secretory Pathway

J. Burbach, M. Nijenhuis, D. Murphy, 2003, Journal of neuroendocrinology.

Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate.

R. V. van Schaik, J. Swen, M. Nijenhuis, 2022, European journal of human genetics : EJHG.

Familial neurohypophysial diabetes insipidus in a large Dutch kindred: effect of the onset of diabetes on growth in children and cell biological defects of the mutant vasopressin prohormone.

J. Burbach, M. Nijenhuis, E. L. van den Akker, 2001, The Journal of clinical endocrinology and metabolism.

TAP polymorphism does not influence transport of peptide variants in mice and humans

R. Obst, M. Nijenhuis, F. Momburg, 1995, European journal of immunology.

Multiple regions of the transporter associated with antigen processing (TAP) contribute to its peptide binding site.

M. Nijenhuis, G. Hämmerling, 1996, Journal of immunology.

A point mutation in the human transporter associated with antigen processing (TAP2) alters the peptide transport specificity

K. Früh, M. Nijenhuis, F. Momburg, 1996, European journal of immunology.

Identification of a contact region for peptide on the TAP1 chain of the transporter associated with antigen processing.

M Nijenhuis, R. Obst, M. Nijenhuis, 1996, Journal of immunology.

Endoplasmic reticulum derangement in hypothalamic neurons of rats expressing a familial neurohypophyseal diabetes insipidus mutant vasopressin transgene

J. Davies, J. Burbach, M. Nijenhuis, 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Early events in the assembly of major histocompatibility complex class II heterotrimers from their free subunits

J. Neefjes, M. Nijenhuis, 1994, European journal of immunology.

Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines

M. Nijenhuis, V. Deneer, H. Abdullah-Koolmees, 2021, Frontiers in Pharmacology.

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

M. Pirmohamed, A. Cambon-Thomsen, Yitian Zhou, 2023, The Lancet.

Pharmacogenetic Information in Clinical Guidelines: The European Perspective

Hans Mulder, H. Guchelaar, J. Swen, 2018, Clinical pharmacology and therapeutics.

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.

R. V. van Schaik, J. Swen, M. Nijenhuis, 2023, European journal of human genetics : EJHG.

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate

R. V. van Schaik, J. Swen, M. Nijenhuis, 2022, European Journal of Human Genetics.

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)

H. Guchelaar, R. V. van Schaik, J. Swen, 2021, European Journal of Human Genetics.

Dutch pharmacogenetics working group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan

R. V. van Schaik, J. Swen, M. Nijenhuis, 2022, European Journal of Human Genetics.